{"nctId":"NCT02263079","briefTitle":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","startDateStruct":{"date":"2014-06-16","type":"ACTUAL"},"conditions":["Pediatric Immuno-Tolerant Chronic Hepatitis B"],"count":62,"armGroups":[{"label":"Peg-IFN-Alfa-2A + Lamivudine or Entecavir","type":"EXPERIMENTAL","interventionNames":["Drug: Entecavir","Drug: Lamivudine","Drug: Pegylated Interferon Alfa-2A"]},{"label":"Untreated Control Participants","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Peg-INF-Alfa-2A Monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated Interferon Alfa-2A"]}],"interventions":[{"name":"Entecavir","otherNames":[]},{"name":"Lamivudine","otherNames":[]},{"name":"Pegylated Interferon Alfa-2A","otherNames":["Pegasys, Peg-IFN-Alfa-2A"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive for HBsAg and HBeAg for more than 6 months prior to baseline\n* Detectable HBV-DNA (\\>20,000 IU/mL) as measured by polymerization chain reaction (PCR) or hybridization on at least 2 occasions at least one month apart with the latest determination obtained less than or equal to (\\</=) 42 days prior to baseline\n* Compensated liver disease (Child-Pugh Class A clinical classification)\n* Either Liver biopsy performed within 2 years prior to baseline showing no or minimal fibrosis (Liver Biopsy Scores and stable normal ALT levels (less than or equal to upper limit of normal \\[ULN\\]) during the 6 months leading up to baseline (including two separate occasions at least 1 month apart over the 6 months prior to baseline). Screening ALT levels must be normal (\\</= ULN) OR Stable normal ALT levels (\\</= ULN), during the 1 year leading up to baseline (including three separate occasions at least 1 month apart over the 1 year prior to baseline) and no signs of hepatocellular carcinoma (HCC), advanced fibrosis/cirrhosis, or splenomegaly on liver abdominal ultrasound at screening. Screening ALT levels must be normal (\\</= ULN)\n\nExclusion Criteria:\n\n* Participants who have received investigational drugs or licensed treatments with anti HBV activity (Exception: Participants who have had a limited \\[\\</= 7-day\\] course of acyclovir for herpetic lesions more than 1 month before the study baseline visit are not excluded)\n* Participants who have participated in any other clinical trial or who have received any investigational drug within 6 months prior to baseline\n* Known hypersensitivity to interferon (IFN), pegylated interferon-alfa-2a or lamivudine or entecavir\n* Positive test results at screening for hepatitis A virus Immunoglobulin M (IgM) antibody (Ab), anti-hepatitis C virus (HCV) Ab, anti- hepatitis D (HDV) Ab or anti-human immunodeficiency virus (HIV) Ab\n* Decompensated liver disease (e.g., Child-Pugh Class B or C clinical classification or clinical evidence such as ascites or varices)\n* Advanced fibrosis or cirrhosis\n* Suspicion of HCC on liver abdominal ultrasound (all patients to have liver abdominal ultrasound within 6 months prior to baseline)\n* History or other evidence of a medical condition associated with chronic liver disease other than CHB including metabolic liver diseases such as hemochromatosis, Wilson's disease or alpha-1 anti-trypsin deficiency\n* Active substance abuse within 6 months prior to screening\n* Sexually active females of childbearing potential and sexually active males who are not willing to utilize reliable contraception during treatment and for 90 days following the end of treatment\n* Females who are pregnant or who are breastfeeding (females of childbearing potential who have a positive urine or serum pregnancy test result within 24 hours of baseline are excluded)","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation","description":"This endpoint is defined as loss of HBsAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80). The percentage of responders (response rate) and 95% CI (using the Clopper-Pearson method) for the response rate are presented for each group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Loss of HBsAg","description":"This endpoint is defined as loss of HBsAg at 1 year post-treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)","description":"This endpoint is defined as loss of HBeAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs","description":"This endpoint measures the seroconversion to anti-HBs defined as loss of HBsAg and presence of anti-HBs at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe","description":"This endpoint measures the seroconversion to anti-HBe defined as loss of HBeAg and presence of anti-HBe at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)","description":"This endpoint measures different HBV DNA levels (\\<20000 IU/mL, \\<2000 IU/mL and undetectable) measured by PCR or hybridization at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-treatment in the treated group. HBV-DNA undetectable is defined as \\<29 IU/mL. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm","description":"This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Peg-INF-Alfa-2A + Lamivudine or Entecavir arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.02","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.54","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.31","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HBV DNA Levels in the Untreated Control Participants","description":"This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Untreated Control arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.22","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.29","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.57","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.24","spread":"2.58"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL","description":"This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \\<20,000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL","description":"This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \\<2000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs)","description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With AEs Leading to Dose Modification or Interruption","description":"This endpoint measures AEs and lab abnormalities leading to dose interruption or dose modification. Does modification included dose reduced, dose increased or drug interrupted. Adverse events included laboratory abnormalities reported as adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Concentration of Peg-INF-Alfa-2A","description":"The serum concentration of Peg-INF-Alfa-2A was measured in picogram/milliliter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8430","spread":"6090"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16300","spread":"10100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13800","spread":"8740"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14900","spread":"7710"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22700","spread":"6070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23000","spread":"4900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19300","spread":"5880"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21900","spread":"14200"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25400","spread":"13100"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["HEADACHE","PYREXIA","ABDOMINAL PAIN UPPER","NAUSEA","FATIGUE"]}}}